Abbott boosts SpectRx holding to 13%:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories is to increase its shareholding in SpectRx, a device maker which is developing a non-invasive glucose monitoring device. Abbott has invested $5.25 million as part of an agreement with Norcross, Georgia-based SpectRx, begun in 1997, increasing its shareholding to 13% from just over 6%. SpectRx is also working with Abbott's rival, Roche Diagnostics, on a screening device based on fluorescence of the eye.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.